Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

FROVATRIPTAN SUCCINATE

All products: not a benefit

Other products in the same Health Canada class (N02CC) — coverage varies; not interchangeable

  • Almotriptan (Axert): not a benefit
  • Eletriptan (Relpax): not a benefit
  • Naratriptan (Amerge): not a benefit
  • Rizatriptan (Maxalt RPD): not a benefit
  • Sumatriptan (Imitrex): not a benefit
  • Zolmitriptan (Zomig Rapimelt): not a benefit

1 more in the class list below

Teva-Frovatriptan · DIN 02415844 · 2.5mg · tablet

Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2026-07-10 — choose a marketed DIN from the same-category list.Discontinued 2026-07-10 · checked 2026-09-20
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2026-07-10 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2026-07-10 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Teva-Frovatriptan · DIN 02415844 Manufacturer: Endo; listing date 2016-03-30 Health Canada: Cancelled post market since 2026-07-10 · brand TEVA-FROVATRIPTAN · ATC N02CC07 FROVATRIPTAN · form Tablet · route Oral · ingredients FROVATRIPTAN (FROVATRIPTAN SUCCINATE) 2.5 MG · company Endo operations ltd. · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90043 · Verify on the e-Formulary ↗ (DIN 02415844)

Source record
DIN 02415844: Teva-Frovatriptan Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 289200052; group id 539; item number 1457; lccId None; manufacturer id EDO Source form: Tab; strength: 2.5mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $12.5033; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02415844 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90043
Interchangeable products
Apo-Frovatriptan · DIN 02426471 · not recorded Frova · DIN 02257084 · not recorded Frovatriptan · DIN 02535475 · not recorded Jamp Frovatriptan · DIN 02497131 · not recorded Mint-Frovatriptan · DIN 02509687 · not recorded
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since 2026-07-10 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (28:92 Miscellaneous Central Nervous System Drugs) and how they are covered

Matched class: 28:92 Miscellaneous Central Nervous System Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: PIZOTYLINE Some products covered without a code (check the product listing): ATOMOXETINE HCL, PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE 28:92 Miscellaneous Central Nervous System Drugs

ALMOTRIPTAN

· 9 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 6.25mg, 12.5mg · Tab

ELETRIPTAN

· 16 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 20mg, 40mg · Tab

NARATRIPTAN HYDROCHLORIDE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1mg, 2.5mg · Tab

RIZATRIPTAN

· 44 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 5mg, 10mg · Orally Disintegrating Tab, Tab

SUMATRIPTAN SUCCINATE

· 37 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 6mg/0.5mL, 25mg, 50mg, 100mg · Inj Sol-Pref Syr 0.5mL Pk, Tab

ZOLMITRIPTAN

· 21 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 2.5mg · Orally Disintegrating Tab, Tab

PIZOTYLINE

· 1 products · General benefit · strengths: 1mg · Tab

ATOMOXETINE HCL

· 59 products · Listed, not a benefit (5), General benefit (40), Off-Formulary Interchangeable, not an ODB benefit (14) · strengths: 10mg, 18mg, 25mg, 40mg, 60mg, 80mg, 100mg · Cap

PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE

· 28 products · General benefit (19), Off-Formulary Interchangeable, not an ODB benefit (7), Listed, not a benefit (2) · strengths: 0.25mg, 0.5mg, 1mg, 1.5mg · Tab

ACAMPROSATE CALCIUM

· 1 products · Limited Use, codes 531 · strengths: 333mg · DR Tab

ENTACAPONE

· 4 products · Limited Use, codes 367 · strengths: 200mg · Tab

DIMETHYL FUMARATE

· 18 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 120mg, 240mg · DR Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:92 and 1 more
Full class listing Related classes: 28:08 Analgesics, 28:10 Opiate Antagonists, 28:12 Anticonvulsants, 28:16 Psychotherapeutic Agents, 28:20 C.N.S. Stimulants, 28:24 Sedatives and Hypnotics, 28:36 Antiparkinsonian Agents Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: migraine attacks with or without aura
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. ALMOTRIPTAN · Off-Formulary Interchangeable, not an ODB benefit INDICATIONS AND CLINICAL USE Adults (> 18 years of age) MYLAN-ALMOTRIPTAN (almotriptan malate) tablets are indicated for the acute treatment of migraine attacks with or without aura. PM: https://pdf.hres.ca/dpd_pm/00035358.PDF; date June 15, 2016; DIN 02398435; fetched 2026-09-10 Product monograph NARATRIPTAN HYDROCHLORIDE · Off-Formulary Interchangeable, not an ODB benefit INDICATIONS AND CLINICAL USE TEVA-NARATRIPTAN (naratriptan hydrochloride) Tablets are indicated for the acute treatment of migraine attacks with or without aura in adults. PM: https://pdf.hres.ca/dpd_pm/00038181.PDF; date February 7, 2017; DIN 02314290; fetched 2026-09-10 Product monograph SUMATRIPTAN SUCCINATE · Off-Formulary Interchangeable, not an ODB benefit Indications IMITREX DF (sumatriptan succinate) and IMITREX (sumatriptan succinate/sumatriptan hemisulphate) are indicated for the acute treatment of migraine attacks with or without aura. PM: https://pdf.hres.ca/dpd_pm/00082699.PDF; date DEC 09, 2025; DIN 02212161; fetched 2026-09-10 Product monograph ZOLMITRIPTAN · Off-Formulary Interchangeable, not an ODB benefit 1 INDICATIONS ZOMIG (zolmitriptan; tablets, orally disintegrating tablets, nasal spray) is indicated for: • the acute treatment of migraine attacks with or without aura, in adults. PM: https://pdf.hres.ca/dpd_pm/00078682.PDF; date Aug 24, 1998; DIN 02238660; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS FROVA (frovatriptan tablets) is indicated for the acute treatment of migraine attacks with or without aura in adults. FROVA is not intended for the prophylactic therapy of migraine or for the use in the management of hemiplegic, ophthalmoplegic or basilar migraine (see 2 CONTRAINDICATIONS). The safety and effectiveness of FROVA have not been established for cluster headache, which is present in an older, predominantly male, population. 1.1 Pediatrics Pediatrics (< 18 years old): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use (see 8.5 Post-Market Adverse Reactions). 1.2 Geriatrics Geriatrics (≥ 65 years old): Because migraine occurs infrequently in the elderly, clinical experience with FROVA is limited in such patients. Limited evidence from clinical studies and experience suggests that the use of FROVA in the geriatric population may be associated with slight differences in safety or effectiveness (see 4.2 Recommended Dose and Dosage Adjustment; 7.1.4 Geriatrics; 10.3 Pharmacokinetics, Special Populations and Conditions, Geriatrics). https://pdf.hres.ca/dpd_pm/00084598.PDF PM date: SEP 03, 2004 Source product: FROVA; DIN 02257084; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Teva-Frovatriptan: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026